Mutations in ZRSR2 have been linked with disease progression in patients with JAK2 V617R – driven myeloproliferative ...

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 CY2025 results topping the market’s revenue ...

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

Incyte (INCY) reported a breakout quarter on Oct. 28, beating Wall Street’s revenue and earnings estimates. Best known for ...

Disc Medicine is planning to launch a trial by year's end to test DISC-3405, its treatment candidate for iron overload, in ...

Incyte on Tuesday raised its annual sales forecast for Jakafi after the cancer drug helped the company post third-quarter results above Wall Street estimates.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is one of the stocks on Jim Cramer’s radar recently. When Cramer was asked about the ...

MPN-U patients exhibit lower platelet counts and higher venous thrombosis rates compared to ET, with thrombosis often ...

Incyte (Nasdaq:INCY) today reported financial results for the third quarter of 2025 and provided a business update.

I am a 68-year-old woman who is in relatively good health. My primary exercise is walking my dogs anywhere from 2-5 miles per day. I have two ...

Swedish Orphan Biovitrum Ab (($GB:0MTD)) announced an update on their ongoing clinical study. Swedish Orphan Biovitrum is conducting a Phase 3 ...